Shigella flexneri 2a Strain CVD 1207, with Specific Deletions in virG, sen, set, and guaBA, Is Highly Attenuated in Humans

A phase 1 clinical trial was conducted among 35 healthy adult volunteers to evaluate the safety, immunogenicity, and shedding of different doses of CVD 1207, a live attenuated Shigella flexneri 2a vaccine candidate with specific deletion mutations in virG, sen, set, and guaBA. CVD 1207 retains the a...

Descripció completa

Dades bibliogràfiques

Publicat a:	Infect Immun
Autors principals:	Kotloff, Karen L., Noriega, Fernando R., Samandari, Taraz, Sztein, Marcelo B., Losonsky, Genevieve A., Nataro, James P., Picking, William D., Barry, Eileen M., Levine, Myron M.
Format:	Artigo
Idioma:	Inglês
Publicat:	American Society for Microbiology (ASM) 2000
Matèries:	Microbial Immunity and Vaccines
Accés en línia:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC97245/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/10678904/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/iai.68.3.1034-1039.2000
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!